CYP3A4抑制剂可能影响[123I]I-FP-CIT SPECT扫描的定量
本研究回顾性分析了6例使用CYP3A4抑制剂者和18例匹配对照者的[123I]I-FP-CIT SPECT,所有受试者扫描均评为正常。结果显示CYP3A4抑制剂使用者的纹状体特异性与非特异性结合比值显著高于对照组(3.52 ± 0.33 vs. 2.90 ± 0.78,p < 0.001)。作者初步结论认为CYP3A4抑制剂可能影响纹状体[123I]I-FP-CIT结合比值,需在更大研究中重复验证。
要点
- [123I]I-FP-CIT部分经CYP3A4代谢为[123I]I-nor-β-CIT,后者对5-羟色胺转运体(SERT)有很高亲和力。
- 使用CYP3A4抑制剂者的纹状体特异性与非特异性[123I]I-FP-CIT结合比值显著高于对照组。
- 作者初步认为CYP3A4抑制剂可能影响[123I]I-FP-CIT SPECT定量,需更大研究重复验证。
核心结论
- 作者初步数据提示,使用CYP3A4抑制剂可能影响纹状体[123I]I-FP-CIT结合比值。
- 作者认为该信息若在更大研究中重复,可能对采用[123I]I-FP-CIT SPECT定量进行诊断或研究具有意义。
研究设计与样本
- 采用回顾性设计,纳入6例使用CYP3A4抑制剂者和18例匹配对照者。
- 仅纳入[123I]I-FP-CIT SPECT扫描评为正常的受试者,所有参与者均在同一脑专用SPECT系统上扫描。
- 使用BRASS软件测定纹状体特异性与非特异性[123I]I-FP-CIT结合比值。
主要发现
- 纹状体特异性与非特异性(以枕叶皮层评估)[123I]I-FP-CIT结合比值在CYP3A4抑制剂使用者中为3.52 ± 0.33,在对照组为2.90 ± 0.78,CYP3A4抑制剂使用者显著高于对照组(p < 0.001)。
临床怎么用
- 作者认为该信息若在更大研究中重复,可能对采用[123I]I-FP-CIT SPECT定量进行诊断或研究具有意义。
局限性
- 作者称本研究为初步数据(preliminary data),并指出需在更大研究中重复验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: [123I]I-FP-CIT SPECT is an imaging tool to support the diagnosis of parkinsonian syndromes characterized by nigrostriatal dopaminergic degeneration. After intravenous injection, [123I]I-FP-CIT is metabolized for a small part by the enzyme CYP3A4, leading to the formation of [123I]I-nor-β-CIT. [123I]I-nor-β-CIT passes the blood-brain barrier and has a very high affinity for the serotonin transporter (SERT). The SERT is expressed in the striatum and cortical areas. So, at least theoretical, the use of frequently used CYP3A4 inhibitors (like amiodarone) may influence the specific to non-specific striatal [123I]I-FP-CIT ratio. Here we tested this novel hypothesis. METHODS: Using a retrospective design, we determined the specific to non-specific striatal [123I]I-FP-CIT ratio (using BRASS software) in 6 subjects that were using an CYP3A4 inhibitor and 18 matched controls. Only subjects were included with a normal rated [123I]I-FP-CIT SPECT scan, and all participants were scanned on the same brain-dedicated SPECT system. RESULTS: The specific to non-specific (assessed in the occipital cortex) striatal [123I]I-FP-CIT binding ratio was significantly higher in CYP3A4 users than in the control group (3.52 ± 0.33 vs. 2.90 ± 0.78, p < 0.001). CONCLUSION: Our preliminary data suggest that the use of CYP3A4 inhibitors may influence striatal [123I]I-FP-CIT binding ratios. This information, when reproduced in larger studies, may be relevant for studies in which quantification of [123I]I-FP-CIT SPECT imaging is used for diagnostic or research purposes.
引用
- Booij J, Yağci E, Sheikh ZH, et al. CYP3A4 inhibitors may influence the quantification of [123I]I-FP-CIT SPECT scans. Eur J Nucl Med Mol Imaging. 2024. PMID: 38730086. doi:10.1007/s00259-024-06748-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。